2nd Quarter - Report

TODD STRATEGY GROUP for ALNYLAM PHARMACEUTICALS, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

LobbyistCovered position, as disclosed
ERIC BERGREN Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
KATHERINE FLEMING COTTON Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
PAUL EDATTEL Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
NICOLAS MAGALLANES Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1672 (119th), H.R. 946 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.